Glenmark Pharmaceuticals reports audited Q4 and FY26 results with dividend recommendation
Glenmark Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- FY26 standalone revenue from operations was ₹8,440.10 crore and total income ₹9,212.12 crore
- FY26 standalone net loss after tax was ₹200.80 crore, compared to profit of ₹1,610.35 crore in FY25
- Board recommended a final dividend of 250% (₹2.5 per equity share) for FY26, subject to shareholder approval
Why it's rated major development: the year-on-year change is 6773% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.